Over and under-utilization of cyclooxygenase-2 selective inhibitors by primary care physicians and specialists
OBJECTIVES: To compare prescribing trends and appropriateness of use of traditional and cyclooxygenase-2 selective (COX-2) nonsteroidal anti-inflammatory drugs (NSAIDs) by primary care physicians (PCPs) and specialists.
DESIGN: Retrospective cohort study.
PATIENTS: One thousand five hundred and seventy-six adult patients continuously enrolled for at least 1 year with an independent practice association of a University-associated managed care plan who were started on a traditional NSAID or a COX-2 inhibitor from 1999 to 2002 and received at least 3 separate medication fills.
MEASUREMENTS: Physician specialty was identified from office visits. Appropriateness of utilization was based on gastrointestinal risk characteristics.
RESULTS: Primary care patients were younger and less likely to have comorbid conditions. Despite similar GI risk, COX-2 use among patients seen by PCPs was half that of patients seen by specialists (21% vs 44%, P<.001). While PCPs overused cyclooxygenase-2-specific inhibitors (COX-2s) less often than specialists (19% vs 41%, P<.001), they also tended to underuse COX-2s in patients who were at increased GI risk (46% vs 32%, P=.063). This represents a 3-fold and 8-fold difference in overuse versus underuse for PCPs and specialists, respectively.
CONCLUSIONS: Using COX-2s as a model for physician adoption of new therapeutic agents, specialists were more likely to use these new medications for patients likely to benefit but were also significantly more likely to use them for patients without a clear indication. This study demonstrates the tension between appropriate adoption of innovative therapies for those individuals who would benefit from their use and those individuals who would receive no added clinical benefit but would incur added cost and be placed at increased risk.
Key wordsprimary care appropriateness COX-2 practice patterns specialist
Unable to display preview. Download preview PDF.
- 1.Center for American Progress. No Relief for Rising Drug Costs. Available at: http://www.americanprogress.org/site/pp.asp?c=biJRJ8OVF&b=83161. Accessed January 31, 2005.Google Scholar
- 6.Fendrick AM, Garabedian-Ruffalo SM. A clinician’s guide to the selection of NSAID therapy. Pharm Ther. 2002;27:579–82.Google Scholar
- 7.Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleveland Clin J Med. 2002;69(Suppl. 1):31-SI39.Google Scholar
- 8.National Institute for Clinical Excellence. Technology Appraisal No. 27. Guidance on the Use of Cyclo-oxygenase (COX) II Selective Inhibitors, Celecoxib, Rofecoxib, Meloxicam and Etodolac for Osteoarthritis and Rheumatoid Arthritis. Available at: http://www.nice.org.uk/pdf/coxiifullguidance.pdf. Accessed January 31, 2005.Google Scholar
- 9.Fendrick AM, Schwartz JS. Physicians’ decisions regarding the acquisition of technology. In: Gelijns AC, Dawkins HV, eds. Medical Innovations at the Crossroads. Vol. 4, Adopting New Medical Technology. Washington, DC: National Academy Press; 1994:71–84.Google Scholar
- 11.Sebaldt RJ, Petrie A, Goldsmith CH, Marentette MA. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in ontario: results from the CANOAR study. Am J Manage Care. 2004;10:742–50.Google Scholar